AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Endpoints: 1. To determine the tumor response rate of AIDS-related Kaposi's sarcoma to topical halofuginone versus vehicle control. 2. To evaluate the safety and tolerability of topical halofuginone and vehicle patients with AIDS-related Kaposi's sarcoma. Secondary Endpoints: 1. To determine the ability of topical halofuginone to inhibit expression of MMP-2 and Collagen type I in AIDA-related Kaposi's sarcoma. 2. To explore the relationship between baseline CD4 and CD8 counts, HIV viral load and HHV-8 viral load and response to halofuginone.